Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin
Conditions
- Chronic Obstructive Pulmonary Disease Exacerbation
- COPD
Interventions
- DRUG: EP395 (Part A and B)
- DRUG: Verapamil (Part A)
- DRUG: Midazolam (Part B)
- DRUG: Digoxin (Part B)
Sponsor
EpiEndo Pharmaceuticals
Collaborators